All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub
Brought to you by Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

CAR-T 2023

Share:

Feb 9, 2023

X post image

11 Feb 2023

CONGRESS | #CART23 Vincenzo Maria Perriello @UniperugiaNews shares in vitro data on a dual targeting CD30/PDL1 CAR-T cell strategy for #cHL. The cells showed higher cytotoxicity and enhanced T-cell proliferation vs single CD30 CAR-T cells.
#lymsm #medicalcongress #hematology

View on 

X post image

11 Feb 2023

CONGRESS | #CART23 Yasmin Nouri @Malaghan_Inst presents preclinical and phase I data on third-generation TLR2 co-stimulated CAR T-cells. Results show enhanced cytotoxicity with reduced inflammatory cytokine production. #lymsm #medicalcongress #hematology

View on 

X post image

11 Feb 2023

CONGRESS | #CART23
Gaurav Narula presents access to CAR-T on a global scale – India. Many treatment challenges exist in this region including patient volume, financial burden, malnutrition and patient tracking. Key clinical trials are ongoing. #lymsm #medicalcongress

View on 

X post image

11 Feb 2023

CONGRESS | #CART23
Kevin Hay @bccancerfdn presents access to CAR-T on a global scale – Canada. While Canada represents global leader in CAR-T cell therapy, access is to treatment is still limited in some areas due to geographical distribution and landscape challenges. #lymsm

View on 

X post image

11 Feb 2023

CONGRESS | #CART23
Candice Hendricks, @UPTuks presents access to CAR-T on a global scale – South Africa. Currently, there is no patient access to CAR-T products for patients in SA. However progress is being made, with early clinical trials expected to start in 2023. #lymsm

View on 

X post image

11 Feb 2023

CONGRESS | #CART23
Roman Hajek presents access to CAR-T on a global scale - Central and Eastern Europe. Discrepancies exist in the availability and reimbursement of CAR-T product cost across the region. Access to clinical trials represents a key challenge for patients. #lymsm

View on 

X post image

11 Feb 2023

CONGRESS | #CART23
@i_yakoub_agha presents updates to European guidelines on CAR T-cell therapy toxicity management, including EBMT/EHA recommendations.
#lymsm #medicalcongress #hematology

View on 

X post image

10 Feb 2023

CONGRESS | #CART23 @knowyournodes share a study of psychosocial experiences in pts with R/R #DLBCL who have received CAR-T. Patients receiving CAR-T are offered and utilize greater levels of support than their peers.
#lymsm #medicalcongress

View on 

X post image

10 Feb 2023

CONGRESS | #CART23
@c_thieblemont, @HopSaintLouis reports long-term analyses from the ELARA trial of tisa-cel in patients with R/R #FL (n=94). Data shows durable efficacy and favorable safety profiles. Median DOR, PFS, TTNT, and OS were not reached. #lymsm #medicalcongress

View on 

X post image

10 Feb 2023

CONGRESS | #CART23 @i_yakoub_agha presents a 3-year follow-up analysis of ZUMA-5. Axi-cel continued to demonstrate durable responses in patients with R/R iNHL. Improved survival was seen in patients with #MZL. No new safety signals were reported. #lymsm #medicalcongress

View on 

X post image

10 Feb 2023

CONGRESS | #CART23 @LiaPalomba @sloankettering presents data from a phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in R/R #kDLBCL. CR=69%, PR=13%, ORR=75%. Responses were seen across all dose levels. Toxicity profile was favorable with low-grade ICANS and CRS. #lymsm

View on 

X post image

10 Feb 2023

CONGRESS | #CART23 @Kersten_MJ @amsterdamumc presents data on the association of metabolic tumor volume and clinical outcome from ZUMA-7 (n=341). High MTV was associated with poorer outcomes with axi-cel, and rates of Grade ≥3 NEs and CRS were associated with higher MTV. #lymsm

View on 

X post image

10 Feb 2023

CONGRESS | #CART23 @BolanosNat and Solène Clavreul lead an informative roundtable discussion of the patient perspective on CAR-T, involving first-hand-accounts of dealing with the side effects of CAR-T therapy, and current challenges facing patients globally. #lymsm

View on 

X post image

9 Feb 2023

CONGRESS | #CART23
@MaxMamonkin, @CAGTHouston discusses CD5 and CD7 targeted CAR T-cell therapy for T-ALL and TCL, highlighting data from the MAGNETA and CRIMSON-NE trials. Both targets can offer advantages, although challenges remain. #lymsm #medicalcongress #hematology

View on 

X post image

9 Feb 2023

CONGRESS | #CART23 @DrMvandenBrink @MSKCancerCenter discusses the role of the intestinal #microbiome in CAR-T therapy. Diet and drugs (particularly antibiotics) can affect the microbiome, and a loss of microbial diversity is associated with worse treatment outcomes. #lymsm

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

CAR-T 2023EHA–EBMT European CAR T-Cell Meeting

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?

Newsletter

Subscribe to get the best content delivered to your inbox